Bill Haney believes there’s a better way to build a biotech — and now he has $100M more at Skyhawk to prove it
Bill Haney wanted to do things differently when he launched Skyhawk Therapeutics at the beginning of the year with $8 million in seed cash from some unconventional biotech backers.
Now he has a $100 million more to focus the team on step 3:
“I think we start driving drugs into the clinic,” he says.
Celgene — which has had more than its share of woes this year — will have a lot to do with that. The big biotech has uncorked one of its classic startup collaborations with Skyhawk, drawn by the emerging field of drugging RNA and the team of scientists at the biotech who are racing to get out front with the new platform play.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
